Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

101.01 +0.92 (+0.92%)
Streaming Delayed Price Updated: 11:03 AM EST, Feb 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
News headline image
Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
From Incyte
Via Business Wire
News headline image
FDA Extends Decision Date For Incyte's Ruxolitinib In Vitiligo Skin Disorder ↗
The FDA has extended the review period for Incyte Corporation's (NASDAQ: INCY) supplemental application for ruxolitinib cream (Opzelura) for vitiligo... 
Via Benzinga
News headline image
Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura™) for the Treatment of Vitiligo
From Incyte Corporation
Via Business Wire
News headline image
Insiders Buy More Than $80M Of 3 Stocks ↗
Although US stock futures traded higher this morning on Friday, there were a few notable insider trades. 
Via Benzinga
News headline image
Expert Ratings For Incyte ↗
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Why Are Incyte Shares Trading Lower Today? ↗
Incyte Corporation's (NASDAQ: INCY)  
Via Benzinga
News headline image
Recap: Incyte Q4 Earnings ↗
  Incyte (NASDAQ:INCY) reported its Q4 earnings results on Tuesday, February 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Why Are Company Insiders Buying These 7 S&P 500 Stocks? ↗
Most investors are likely familiar with the adage, "actions speak louder than words." That saying certainly applies to the executives and other corporate insiders buying... 
Via Benzinga
News headline image
Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients ↗
According to a British study, Eli Lilly And Co (NYSE: LLY) and Incyte Corporation's (NASDAQ: INCY) Olumiant (baricitinib) reduced the risk of death in... 
Via Benzinga
News headline image
CTI BioPharma's Bone Marrow Cancer Drug Scores FDA Approval ↗
The FDA approved CTI BioPharma Corp's (NASDAQ: CTIC) Vonjo (pacritinib) for treating adult patients with myelofibrosis, a type of bone marrow cancer with low... 
Via Benzinga
News headline image
Insiders Buying Incyte And 2 More Stocks ↗
Although U.S. stock futures traded higher this morning after recording losses on Tuesday, there were a few notable insider trades. When i... 
Via Benzinga
News headline image
7 Insider Stocks to Buy as Execs Snap Them Up ↗
With equity prices soaring to record levels, many execs have cashed out. Here are the insider stocks where execs are cashing in. 
Via InvestorPlace
News headline image
Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema ↗
Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE: LLY) has decided to  
Via Benzinga
News headline image
Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus ↗
Incyte Corporation (NASDAQ: INCY) is  
Via Benzinga
News headline image
Where Incyte Stands With Analysts ↗
Within the last quarter, Incyte (NASDAQ:INCY) has observed the following an... 
Via Benzinga
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Insiders Buy Around $112M Of 3 Stocks ↗
US stock futures traded higher on Tuesday, amid reports that some Russian troops are returning to their bases. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Oncolytics Announced Updates On Clinical Trials Of New Treatment For Triple-Negative Metastatic Breast Cancer ↗
Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2022 ↗
Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs
From Incyte Corporation
Via Business Wire
News headline image
Bear Market Bets In Biotech ↗
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020. 
Via Talk Markets
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Earnings Scheduled For February 8, 2022 ↗
Companies Reporting Before The Bell • Pfizer (NYSE:PFE) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
News headline image
Incyte Provides Update on Parsaclisib and MCLA-145
From Incyte
Via Business Wire
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s... 
Via FinancialNewsMedia
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022 ↗
Upgrades Canaccord Genuity upgraded the previous rating for Fortuna Silver Mines Inc (NYSE: 
Via Benzinga
News headline image
Incyte to Report Fourth Quarter and Year-End 2021 Financial Results
From Incyte
Via Business Wire
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer... 
Via FinancialNewsMedia
Topics Death
< Previous 1 2
...
20 21 22 23 24 25 26 27 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.